Alivus Life Sciences (ALIVUS) | Stock Overview & Key Data
Alivus Life Sciences Performance Comparison
Stock Range
Today's Range
Low: ₹935.75
High: ₹952.00
on September 18, 2025
52 Week Range
Low: ₹850.00
High: ₹1,251.00
on April 7, 2025
on February 6, 2025
All-Time High: ₹1,251.00 on February 3, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR115.0B
EPS
40.29
P/E Ratio (TTM)
23.10
Forward P/E
18.70
P/B Ratio
4.05
PEG Ratio
2.59
Div. Yield
N/A
ROE
17.24%
Beta
0.113
Debt to Equity
2.01
Financial Highlights
Profitability
Gross Margin
55.07%
Operating Margin
25.80%
Profit Margin
20.65%
Returns and Earnings
Return on Assets (TTM)
14.24%
Return on Equity (TTM)
17.24%
EBITDA
INR7.3B
Net Income (TTM)
INR5.0B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR195.87
Quarterly Revenue Growth (YoY)
2.20%
Quarterly Earnings Growth (YoY)
9.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Alivus Life Sciences ALIVUS | 114.96B Mid-cap | 0.23% | -0.97% | -5.77% | -11.16% | -4.24% | -12.68% | -12.68% | -12.68% |
| Sun Pharmaceutical SUNPHARMA | 3.94T Large-cap | 2.42% | 0.97% | 0.04% | -3.27% | -12.77% | -11.64% | 78.98% | 236.69% |
| Divi's Laboratories DIVISLAB | 1.62T Large-cap | 1.60% | -0.85% | -6.67% | 7.78% | 0.64% | 12.13% | 67.79% | 99.69% |
| Alembic APLLTD | 191.31B Mid-cap | 1.08% | -1.48% | -0.15% | 16.47% | -8.74% | -14.14% | 57.11% | 0.24% |
| Jubilant Pharmova JUBLPHARMA | 179.71B Mid-cap | -0.84% | 5.83% | -0.73% | 30.24% | 3.26% | -7.54% | 232.57% | 106.62% |
| Caplin Point CAPLIPOINT | 170.99B Mid-cap | 3.75% | 7.89% | 11.14% | 25.53% | -7.59% | 19.69% | 223.53% | 320.37% |
Ownership & Short Interest
Insider Ownership
76.13%
Institutional Ownership
7.61%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
60K
Average 90-Day Volume
88K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ALIVUS's 52-week high and low?
- In the last 52 weeks, Alivus Life Sciences reached a high of ₹1,251.00 (on February 6, 2025) and a low of ₹850.00 (on April 7, 2025).
- What is the market cap and P/E ratio for ALIVUS?
- Curious about Alivus Life Sciences's size and valuation? Its market capitalization stands at 114.96B. When it comes to valuation, the P/E ratio (trailing twelve months) is 23.10, and the forward P/E (looking ahead) is 18.70.
- Does ALIVUS pay dividends? If so, what's the yield?
- As for dividends, Alivus Life Sciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Alivus Life Sciences's main competitors or similar companies to consider before investing?
When looking at Alivus Life Sciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.94T Healthcare Drug Manufacturers - Specialty & Generic -11.64% 78.98% Divi's Laboratories
DIVISLAB1.62T Healthcare Drug Manufacturers - Specialty & Generic 12.13% 67.79% Alembic
APLLTD191.31B Healthcare Drug Manufacturers - Specialty & Generic -14.14% 57.11% Jubilant Pharmova
JUBLPHARMA179.71B Healthcare Drug Manufacturers - Specialty & Generic -7.54% 232.57% Caplin Point
CAPLIPOINT170.99B Healthcare Drug Manufacturers - Specialty & Generic 19.69% 223.53% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Alivus Life Sciences Limited? (e.g., ROE, Debt/Equity)
- To get a sense of Alivus Life Sciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 17.24%, the Debt to Equity ratio from the most recent quarter is 2.01, and its Gross Profit Margin stands at 55.07%.
- What is the recent revenue and earnings growth for ALIVUS?
- Looking at Alivus Life Sciences's growth, its revenue over the trailing twelve months (TTM) was INR24B. Compared to the same quarter last year (YoY), quarterly revenue grew by 2.20%, and quarterly earnings saw a YoY growth of 9.00%.
- How much of ALIVUS stock is held by insiders and institutions?
- Wondering who owns Alivus Life Sciences stock? Company insiders (like executives and directors) hold about 76.13% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 7.61%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.